Severina D. F.
- Country
- Spain
- Department
- Oncology Service
Research Overview
- Phase III Randomized, Double-Blind Trial of Atezolizumab with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
- Phase II Evaluation of Trastuzumab, Tucatinib, and Vinorelbine in HER2-Positive Non-Resectable Locally Advanced or Metastatic Breast Cancer
- LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES
Data & Insights
Has run more than one trial at 24 of 159 partner sites.
Specializations
Advanced Breast Cancer Treatment
Specializes in developing therapeutic approaches for HER2-positive metastatic breast cancer, with particular focus on combination therapies involving targeted treatments and chemotherapy agents.
- Non-resectable locally advanced breast cancer
- Metastatic breast cancer management
- HER2-positive disease interventions
Investigates novel therapeutic combinations to enhance treatment outcomes in advanced disease stages.
Early-Stage Breast Cancer Research
Conducts comprehensive research on early-stage invasive breast cancer, focusing on disease progression patterns and treatment outcomes in neoadjuvant and adjuvant settings.
- Long-term patient monitoring
- Relapse pattern analysis
- Treatment response evaluation
Explores the long-term evolution of breast cancer in early stages through systematic clinical observation.
Innovative Therapeutic Approaches
Leads investigations in triple-negative breast cancer and HER2-negative breast cancer treatments, incorporating immunotherapy and targeted therapeutic strategies.
- Neoadjuvant chemotherapy protocols
- Immunotherapy applications
- High-risk disease management
Focuses on developing personalized treatment approaches for various breast cancer subtypes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.